Kilgallen Aoife B, Štibler Urška, Printezi Markella I, Putker Marrit, Punt Cornelis J A, Sluijter Joost P G, May Anne M, van Laake Linda W
Regenerative Medicine Centre, University Medical Centre Utrecht, Utrecht, Netherlands.
Division Heart and Lungs, University Medical Centre Utrecht, Utrecht, Netherlands.
JMIR Res Protoc. 2020 Oct 21;9(10):e18023. doi: 10.2196/18023.
Chronomodulated chemotherapy aims to achieve maximum drug safety and efficacy by adjusting the time of treatment to an optimal biological time as determined by the circadian clock. Although it is a promising alternative to conventional (non-time-stipulated) chemotherapy in several instances, the lack of scientific consensus and the increased logistical burden of timed administration limit the use of a chronomodulated administration protocol.
With the goal to increase scientific consensus on this subject, we plan to conduct a systematic review of the current literature to compare the drug safety and efficacy of chronomodulated chemotherapy with those of conventional chemotherapy.
This systematic review will comply with the PRISMA (Preferred Reporting Items for the Systematic Reviews and Meta-Analysis) guidelines. In order to identify relevant studies, we conducted a comprehensive search in PubMed and Embase on May 18, 2020. We included clinical studies that compare either the safety or efficacy of chronomodulated chemotherapy with that of conventional chemotherapy. Potential studies will be reviewed and screened by 2 independent reviewers. Quality assessment will be performed using the National Institutes of Health's Study Quality Assessment Tool (Quality Assessment of Controlled Intervention Studies). Disagreements will be resolved by consulting a third independent reviewer.
This protocol has received funding, and the search for studies from databases commenced on May 18, 2020. The systematic review is planned to be completed by October 31, 2020.
In this systematic review, we will compare drug safety and drug efficacy for cancer patients who were administered either chronomodulated chemotherapy or conventional chemotherapy. Moreover, we will highlight the outcomes and quality of the selected trials for this review.
PROSPERO International Prospective Register of Systematic Reviews CRD42020177878; https://tinyurl.com/y53w9nq6.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/18023.
时辰调节化疗旨在通过将治疗时间调整至由生物钟确定的最佳生物学时间，以实现最大的药物安全性和疗效。尽管在某些情况下，它是传统（非定时）化疗的一种有前景的替代方法，但缺乏科学共识以及定时给药带来的后勤负担增加限制了时辰调节给药方案的使用。
为了就该主题增加科学共识，我们计划对当前文献进行系统评价，以比较时辰调节化疗与传统化疗的药物安全性和疗效。
本系统评价将遵循PRISMA（系统评价和Meta分析的首选报告项目）指南。为了识别相关研究，我们于2020年5月18日在PubMed和Embase中进行了全面检索。我们纳入了比较时辰调节化疗与传统化疗的安全性或疗效的临床研究。潜在研究将由2名独立 reviewers 进行审查和筛选。将使用美国国立卫生研究院的研究质量评估工具（对照干预研究的质量评估）进行质量评估。分歧将通过咨询第三位独立 reviewer 来解决。
本方案已获得资金，并且于2020年5月18日开始从数据库中检索研究。系统评价计划于2020年10月31日前完成。
在本系统评价中，我们将比较接受时辰调节化疗或传统化疗的癌症患者的药物安全性和疗效。此外，我们将突出本次评价所选试验的结果和质量。
PROSPERO国际前瞻性系统评价注册库CRD42020177878；https://tinyurl.com/y53w9nq6。
国际注册报告识别号（IRRID）：PRR1-10.2196/18023。
